Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Fu-Jen Lee"'
Autor:
Yu‐Tse Chiu, Fu‐Jen Lee, Chen‐Ya Kuo, Yang‐Chao Lin, Kai‐Shun Liang, Liang‐Wei Tseng, Yu‐Tsung Chen, Chi‐Yang Chang
Publikováno v:
JGH Open, Vol 7, Iss 2, Pp 105-109 (2023)
Abstract Background and Aim Vonoprazan as a new acid blocker has more potency and longer lasting acid suppression than proton pump inhibitors. Whether the efficacy of vonoprazan‐based triple therapy is comparable with or even better than that of cu
Externí odkaz:
https://doaj.org/article/64f215c9466e4773b9c555b32064393e
Autor:
Yao-Chun Hsu, Chih-Cheng Chen, Wei-Hsiang Lee, Chi-Yang Chang, Fu-Jen Lee, Cheng-Hao Tseng, Tzu-Haw Chen, Hsiu J. Ho, Jaw-Town Lin, Chun-Ying Wu
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-10 (2022)
Abstract It is unclear whether dysbiosis in hepatitis C virus (HCV) infected patients results from the viral infection per se or develops as a result of hepatic dysfunction. We aimed to characterize compositions in gut microbiome before and shortly a
Externí odkaz:
https://doaj.org/article/ba4ee11fad7d4a15a590a858789c3f5f
Autor:
Chen-Hua Liu, Chi-Yi Chen, Wei-Wen Su, Chun-Jen Liu, Ching-Chu Lo, Ke-Jhang Huang, Jyh-Jou Chen, Kuo-Chih Tseng, Chi-Yang Chang, Cheng-Yuan Peng, Yu-Lueng Shih, Chia-Sheng Huang, Wei-Yu Kao, Sheng-Shun Yang, Ming-Chang Tsai, Jo-Hsuan Wu, Po-Yueh Chen, Pei-Yuan Su, Jow-Jyh Hwang, Yu-Jen Fang, Pei-Lun Lee, Chi-Wei Tseng, Fu-Jen Lee, Hsueh-Chou Lai, Tsai-Yuan Hsieh, Chun-Chao Chang, Chung-Hsin Chang, Yi-Jie Huang, Jia-Horng Kao
Publikováno v:
Clinical and Molecular Hepatology, Vol 27, Iss 4, Pp 575-588 (2021)
Background/Aims Real-world studies assessing the effectiveness and safety of sofosbuvir/velpatasvir (SOF/VEL) plus ribavirin (RBV) for Child-Pugh B/C hepatitis C virus (HCV)-related cirrhosis are limited. Methods We included 107 patients with Child-P
Externí odkaz:
https://doaj.org/article/4ef4e404f00c418597db8898e8c2d587
Autor:
Ting-Yu Chang, Chien-Hsien Wu, Chi-Yang Chang, Fu-Jen Lee, Bei-Wen Wang, Jia-Yau Doong, Yu-Shun Lin, Chang-Sheng Kuo, Rwei-Fen S. Huang
Publikováno v:
Nutrients, Vol 14, Iss 2, p 261 (2022)
Few studies on humans have comprehensively evaluated the intake composition of methyl-donor nutrients (MDNs: choline, betaine, and folate) in relation to visceral obesity (VOB)-related hepatic steatosis (HS), the hallmark of non-alcoholic fatty liver
Externí odkaz:
https://doaj.org/article/e71aa21b618640c29224fa2d31390de5
Autor:
Chen-Hua Liu, Cheng-Yuan Peng, Chun-Jen Liu, Chi-Yi Chen, Ching-Chu Lo, Kuo-Chih Tseng, Pei-Yuan Su, Wei-Yu Kao, Ming-Chang Tsai, Hung-Da Tung, Hao-Tsai Cheng, Fu-Jen Lee, Chia-Sheng Huang, Ke-Jhang Huang, Yu-Lueng Shih, Sheng-Shun Yang, Jo-Hsuan Wu, Hsueh-Chou Lai, Yu-Jen Fang, Po-Yueh Chen, Jow-Jyh Hwang, Chi-Wei Tseng, Wei-Wen Su, Chun-Chao Chang, Pei-Lun Lee, Jyh-Jou Chen, Chi-Yang Chang, Tsai‐Yuan Hsieh, Chung-Hsin Chang, Yi-Jie Huang, Jia-Horng Kao
Publikováno v:
Hepatology International. 17:291-302
Background Real-world data are scarce about the effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) for retreating East Asian patients with hepatitis C virus (HCV) infection who previously received NS5A direct-acting antivir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0dcfd15b389d31b91ddcc700f4bc56b
https://doi.org/10.1007/s12072-022-10475-9
https://doi.org/10.1007/s12072-022-10475-9
Autor:
Yu‐Tse Chiu, Fu‐Jen Lee, Chen‐Ya Kuo, Yang‐Chao Lin, Kai‐Shun Liang, Liang‐Wei Tseng, Yu‐Tsung Chen, Chi‐Yang Chang
Publikováno v:
JGH Open. 7:105-109
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4cb95c6c05498bac836b6445e4be0c99
https://doi.org/10.1002/jgh3.12858
https://doi.org/10.1002/jgh3.12858
Publikováno v:
Medicine. 101(29)
Adequate bowel preparation is an essential part of a high-quality colonoscopy. Recent studies showed that the small-volume bowel cleansing agent Bowklean performs better in terms of tolerability and acceptability. However, its split-dose regimen is s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49f141550bb024178256b76cd06cb5c3
https://pubmed.ncbi.nlm.nih.gov/35866774
https://pubmed.ncbi.nlm.nih.gov/35866774
Autor:
Sheng-Shun Yang, Chi Wei Tseng, Chien-Ching Hung, Ching Chu Lo, Ming-Chang Tsai, Chun Chao Chang, Jia-Horng Kao, Chi Yang Chang, Chung Hsin Chang, Yu Jen Fang, Chia Sheng Huang, Ke Jhang Huang, Tsai‐Yuan ‐Y Hsieh, Cheng Yuan Peng, Hsueh Chou Lai, Pei Lun Lee, Wei Wen Su, Po-Yueh Chen, Chen-Hua Liu, Chi Yi Chen, Jow Jyh Huang, Yi Jie Huang, Wei-Yu Kao, Chun-Jen Liu, Kuo Chih Tseng, Jyh Jou Chen, Pei Yuan Su, Fu Jen Lee, Yu-Lueng Shih
Publikováno v:
Hepatology International. 15:338-349
Data regarding the real-world effectiveness and safety of sofosbuvir/velpatasvir (SOF/VEL) for East Asian patients with chronic hepatitis C virus (HCV) infection and compensated liver disease are limited. We evaluated the performance of SOF/VEL for 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::06ef0d14ab5bc903444da29fd7dd467e
https://doi.org/10.1007/s12072-021-10158-x
https://doi.org/10.1007/s12072-021-10158-x
Publikováno v:
Cancers
Volume 15
Issue 4
Pages: 1148
Volume 15
Issue 4
Pages: 1148
Previous studies have indicated that HBV infection and T2DM are the factors that increase the risk of developing HCC. The experimental evidence has shown that antiglycemic agents may reduce the risk of HCC. However, the effect of dipeptidyl peptidase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9e020c8f8703d432bba923dfc4e2e90
https://doi.org/10.3390/cancers15041148
https://doi.org/10.3390/cancers15041148
Autor:
Chen-Hua Liu, Po-Yueh Chen, Jyh-Jou Chen, Ching-Chu Lo, Wei-Wen Su, Kuo-Chih Tseng, Chun-Jen Liu, Chia-Sheng Huang, Ke-Jhang Huang, Sheng-Shun Yang, Cheng-Yuan Peng, Ming-Chang Tsai, Wei-Yu Kao, Chi-Yang Chang, Yu-Lueng Shih, Yu-Jen Fang, Chi-Yi Chen, Pei-Lun Lee, Jow-Jyh Huang, Pei-Yuan Su, Chi-Wei Tseng, Chien-Ching Hung, Chung-Hsin Chang, Yi-Jie Huang, Hsueh-Chou Lai, Chun-Chao Chang, Fu-Jen Lee, Tsai‐Yuan Hsieh, Jia-Horng Kao
Background Data regarding the real-world effectiveness and safety of sofosbuvir/velpatasvir (SOF/VEL) for East Asian patients with chronic hepatitis C virus (HCV) infection and compensated liver disease are limited. We evaluated the performance of SO
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ddb50dddc97877adbdfb81604dba53b0
https://doi.org/10.21203/rs.3.rs-198227/v1
https://doi.org/10.21203/rs.3.rs-198227/v1
